FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956183784> ?p ?o ?g. }

• W2956183784 endingPage "e539" @default.
• W2956183784 startingPage "e531" @default.
• W2956183784 abstract "Background Accurately estimating HIV disease progression and retention on antiretroviral therapy (ART) can help inform interventions to control HIV microepidemics and mathematical models used to inform health-resource allocation decisions. Our objective was to estimate the monthly probabilities of on-ART CD4 T-cell count progression, mortality, ART dropout, and ART reinitiation using a continuous-time multistate Markov model. We also aimed to validate health-state transition probability estimates to ensure they accurately reproduced the regional HIV microepidemics across the USA. Methods In our modelling study, we considered a cohort of patients from the HIV Research Network, a consortium of 17 adult and paediatric HIV-care providers located in the northeastern (n=8), southern (n=5), and western (n=4) regions of the USA. Individuals aged 15 years or older who were in HIV care (defined as one CD4 test and one HIV-care visit in a calendar year period) with at least one ART prescription between Jan 1, 2010, and Dec 31, 2015, were included in the analysis. We used continuous-time multistate Markov models to estimate transitions between CD4 strata and between on-ART and off-ART states. We examined and adjusted for differences in probability of transition by region, race or ethnicity, sex, HIV risk group, and other baseline clinical indicators. Findings The median age of the 32 242 individuals included in the analysis was 44 years (interquartile range 35–51). Over a median follow-up of 4·9 years (2·6–6·0), 8614 (26·7%) of 32 242 people interrupted ART and 1325 (4·1%) of 32 242 people died. Women, men who have sex with men, and individuals with no previous ART experience had greater increases in CD4 cell counts, whereas black people and people who inject drugs had increased probabilities of ART dropout and faster disease progression. Regardless of CD4 strata, individuals had increased hazard for ART dropout if they were from the south (adjusted hazard ratio [aHR] range from 1·91, 95% CI 1·71–2·13, to 2·45, 2·29–2·62) or the west (aHR range from 1·29, 1·10–1·51, to 1·66, 1·51–1·82) of the USA, compared with individuals from the northeast USA. Interpretation Our results show heterogeneities in disease progression during ART and probability of ART retention across race and ethnicity, HIV risk groups, and regions. These differences should be viewed as targets for intervention and should be incorporated in mathematical models of regional HIV microepidemics in the USA. Funding US National Institutes of Health, Agency for Healthcare Research and Quality, and Health Resources and Services Administration." @default.
• W2956183784 created "2019-07-23" @default.
• W2956183784 creator A5004515094 @default.
• W2956183784 creator A5008655290 @default.
• W2956183784 creator A5016694106 @default.
• W2956183784 creator A5016804273 @default.
• W2956183784 creator A5021428464 @default.
• W2956183784 creator A5025339106 @default.
• W2956183784 creator A5030823207 @default.
• W2956183784 creator A5034961321 @default.
• W2956183784 creator A5037879583 @default.
• W2956183784 creator A5043060259 @default.
• W2956183784 creator A5045732749 @default.
• W2956183784 creator A5048622777 @default.
• W2956183784 creator A5050128023 @default.
• W2956183784 creator A5050514045 @default.
• W2956183784 creator A5058807462 @default.
• W2956183784 creator A5059935433 @default.
• W2956183784 creator A5060967525 @default.
• W2956183784 creator A5065274638 @default.
• W2956183784 creator A5067438112 @default.
• W2956183784 creator A5067905523 @default.
• W2956183784 creator A5069032071 @default.
• W2956183784 creator A5074418085 @default.
• W2956183784 creator A5074839081 @default.
• W2956183784 creator A5075173406 @default.
• W2956183784 creator A5075272604 @default.
• W2956183784 creator A5077949168 @default.
• W2956183784 creator A5083705730 @default.
• W2956183784 creator A5084424394 @default.
• W2956183784 creator A5085534148 @default.
• W2956183784 creator A5088567641 @default.
• W2956183784 creator A5088973456 @default.
• W2956183784 date "2019-08-01" @default.
• W2956183784 modified "2023-10-15" @default.
• W2956183784 title "Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study" @default.
• W2956183784 cites W1482581820 @default.
• W2956183784 cites W1506560069 @default.
• W2956183784 cites W1919480245 @default.
• W2956183784 cites W1979525590 @default.
• W2956183784 cites W1991263017 @default.
• W2956183784 cites W2006946907 @default.
• W2956183784 cites W2030490945 @default.
• W2956183784 cites W2037366757 @default.
• W2956183784 cites W2039617800 @default.
• W2956183784 cites W2052696866 @default.
• W2956183784 cites W2063141697 @default.
• W2956183784 cites W2081070967 @default.
• W2956183784 cites W2085807998 @default.
• W2956183784 cites W2095718569 @default.
• W2956183784 cites W2101924020 @default.
• W2956183784 cites W2122795395 @default.
• W2956183784 cites W2130358353 @default.
• W2956183784 cites W2133022890 @default.
• W2956183784 cites W2134023402 @default.
• W2956183784 cites W2136677864 @default.
• W2956183784 cites W2162935397 @default.
• W2956183784 cites W2235498348 @default.
• W2956183784 cites W2253726780 @default.
• W2956183784 cites W2415238254 @default.
• W2956183784 cites W2554116060 @default.
• W2956183784 cites W2727019413 @default.
• W2956183784 cites W2795340916 @default.
• W2956183784 cites W2803339509 @default.
• W2956183784 cites W2807247400 @default.
• W2956183784 doi "https://doi.org/10.1016/s2352-3018(19)30148-1" @default.
• W2956183784 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6693664" @default.
• W2956183784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31303557" @default.
• W2956183784 hasPublicationYear "2019" @default.
• W2956183784 type Work @default.
• W2956183784 sameAs 2956183784 @default.
• W2956183784 citedByCount "16" @default.
• W2956183784 countsByYear W29561837842019 @default.
• W2956183784 countsByYear W29561837842020 @default.
• W2956183784 countsByYear W29561837842021 @default.
• W2956183784 countsByYear W29561837842022 @default.
• W2956183784 countsByYear W29561837842023 @default.
• W2956183784 crossrefType "journal-article" @default.
• W2956183784 hasAuthorship W2956183784A5004515094 @default.
• W2956183784 hasAuthorship W2956183784A5008655290 @default.
• W2956183784 hasAuthorship W2956183784A5016694106 @default.
• W2956183784 hasAuthorship W2956183784A5016804273 @default.
• W2956183784 hasAuthorship W2956183784A5021428464 @default.
• W2956183784 hasAuthorship W2956183784A5025339106 @default.
• W2956183784 hasAuthorship W2956183784A5030823207 @default.
• W2956183784 hasAuthorship W2956183784A5034961321 @default.
• W2956183784 hasAuthorship W2956183784A5037879583 @default.
• W2956183784 hasAuthorship W2956183784A5043060259 @default.
• W2956183784 hasAuthorship W2956183784A5045732749 @default.
• W2956183784 hasAuthorship W2956183784A5048622777 @default.
• W2956183784 hasAuthorship W2956183784A5050128023 @default.
• W2956183784 hasAuthorship W2956183784A5050514045 @default.
• W2956183784 hasAuthorship W2956183784A5058807462 @default.
• W2956183784 hasAuthorship W2956183784A5059935433 @default.
• W2956183784 hasAuthorship W2956183784A5060967525 @default.
• W2956183784 hasAuthorship W2956183784A5065274638 @default.
• W2956183784 hasAuthorship W2956183784A5067438112 @default.
• W2956183784 hasAuthorship W2956183784A5067905523 @default.

• next